Skip to main content
. 2023 Mar 27;53(5):294–312. doi: 10.4070/kcj.2023.0024

Figure 2. Guideline-directed medical therapy adherence in landmark randomized controlled trial.

Figure 2

ACEI = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor blocker; ARNI = angiotensin receptor/neprilysin inhibitor; BB = beta-blocker; DAPA-HF = Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure; EMPEROR-Reduced = Empagliflozin Outcome Trial in Patients with Chronic Heart Failure and Reduced Ejection Fraction; GALACTIC-HF = Global Approach to Lowering Adverse Cardiac Outcomes through Improving Contractility in Heart Failure; MRA = mineralocorticoid antagonist; SGLT2I = sodium-glucose cotransporter-2 inhibitor; VICTORIA = Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction.